Share on LinkedInShare on LinkedIn

ARTICLE · 19 MAY 2020

Quick Reference Guide: Compulsory Patent Licensing During COVID-19 Crisis

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

The novel coronavirus (COVID-19) pandemic and the economic impact of lock-down or shelter-in-place orders create new risks every day.

United StatesIntellectual Property

The novel coronavirus (COVID-19) pandemic and the economic impact of lock-down or shelter-in-place orders create new risks every day. One risk to pharmaceutical, life sciences, and other health care technology companies as research on COVID-19 treatments and vaccines progress is the risk that the patents related to those treatments and vaccines may be suspended or involuntarily licensed to governments and even competitors. Assessing these risks, the impact that compulsory licensing may have on investments in research and new product development, and the potential for compulsory licenses in key jurisdictions being granted to resulting intellectual property rights, is essential to any business strategy for companies developing technology related to COVID-19.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from